Category archives: Events

Virtual – PosterAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present additional efficacy endpoints of OVX836 as part of a poster entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “A new approach towards a universal influenza vaccine: clinical update of OVX836”. 

Lyon – Oral PresentationDelphine Guyon-Gellin, Chief of Business Development of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “A new approach towards a universal influenza vaccine: clinical update of OVX836”. 

Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

Virtual – PosterAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present the last clinical results of OVX836 as part of a poster entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

Lyon – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a general update on OVX836 as part of a presentation entitled “the development of a universal influenza vaccine: a precision approach to control diversity – NP as an attractive target for T cell based universal flu vaccine.”

Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

Lille – Oral PresentationFlorence Nicolas, Director of R&D and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled “A novel universal influenza vaccine candidate: Short-term results of the Phase 1 clinical trial”.

Boston – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled “A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans”.